Karamvir Yadav, Medical Oncologist at Harish Renova Hospital, shared a post on LinkedIn:
“Can previously effective therapies be successfully reused in neuroendocrine tumors (NETs)?
A new review in Cancer Treatment Reviews examines the evolving role of retreatment and rechallenge strategies in advanced NETs—a concept that is becoming increasingly relevant as patients live longer and receive multiple lines of therapy.
Key insights:
- PRRT retreatment currently has the strongest supporting evidence, with disease control rates approaching 70%.
- A longer treatment-free interval appears to be one of the most important predictors of benefit across treatment classes.
- Retreatment with alkylating agents (e.g., temozolomide-based regimens) may provide renewed disease stabilization, particularly in pancreatic NETs.
- Emerging biomarkers such as MGMT status and individualized PRRT dosimetry may help refine patient selection in the future.
- Rechallenge is not necessarily about achieving new tumor responses—it is about extending disease control, preserving quality of life, and maximizing therapeutic sequencing.
As the therapeutic landscape of NETs continues to expand, the challenge will be moving from empiric retreatment decisions toward biomarker-driven, personalized strategies.
What factors currently influence your decision to consider PRRT retreatment or systemic therapy rechallenge in NET patients?”
Other articles featuring Karamvir Yadav on OncoDaily.